Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clensia is a low-volume, macrogol-based osmotic laxative used for bowel cleansing prior to clinical procedures such as colonoscopy or radiological imaging. It is a multi-component formulation containing macrogol 4000, anhydrous sodium sulfate, sodium citrate, citric acid, sodium chloride, potassium chloride, and simethicone. The macrogol and salts work by increasing the osmotic pressure in the bowel, leading to water retention and an increased volume of stool, which stimulates peristalsis. Simethicone is included as an anti-foaming agent to reduce gas bubbles and improve mucosal visualization during endoscopy. It is typically administered as a two-liter solution and is marketed by Alfasigma.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Clensia.